The future of the global HIV response risks being undermined by shrinking funding and wavering political will, health leaders have warned as the International AIDS Society (IAS) Conference on HIV ...

The WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

A breakthrough to reduce risk of HIV in adolescents and adults weighing at least 35 kg. WHO releases the new guidelines ...

The World Health Organization now recommends lenacapavir, a twice-yearly injectable HIV prevention drug, especially for high-risk groups. This endorse ...

GENEVA, (CMC)-The World Health Organization (WHO) on Monday advised countries, including those in the Caribbean to ensure ...

New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...

The WHO chief on Monday called on world leaders to prioritize HIV prevention and embrace meaningful partnerships in an effort ...

The global recommendation – issued Monday at the International AIDS Conference in Kigali, Rwanda – comes about a month after ...

The World Health Organization (WHO) has issued new guidelines recommending the twice-yearly use of injectable lenacapavir ...